The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Evaluating Biosimilar Programs and Formularies
Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans
Tracking Usage and Monitoring the Impact of Biosimilars
Protocols and Laws for Transitioning to Biosimilars
Transitioning to a Biosimilar Program
Increased Use of Biosimilars
Optimizing Transitions to Biosimilars
Optimizing Transitions to Biosimilars Continued
Biosimilars Are Getting a Foothold and Becoming Preferred, Says Dr James Chambers
Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars
Role of the Pharmacist in the Care Team to Contain Costs in Oncology
Private Label Biosimilars
Dr Kimberly Maxfield Discusses FDA Actions Since BsUFA III Reauthorization
Dr Sophia Humphreys Speaks on Biosimilars in Formulary Management
Dr Jorge Garcia Speaks About Ambulatory Drug Infusion, Infusion Therapy
Dr Kimberly Maxfield Highlights FDA's Education Efforts to Increase Biosimilar Comfort
Patient, Provider Education and Payer Management Can Improve Biosimilar Uptake: Dr Bincy Abraham
Biosimilars Had a Huge Impact on Total Cost of Care, Says AON’s Christine Pfaff
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required
Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient
Biosimilars Are Being Approved but Not Reaching the Market
Progress in the US With Biosimilars, but Opportunities Remain
Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News
Podcast: This Week in Managed Care—Verma on Health Data and Other Health News
The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange
Podcast: This Week in Managed Care—New Voluntary Payment Model and Other Health News
Exploring the Complexities of Biosimilars and Interchangeability